pioglitazone has been researched along with osteoprotegerin in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 5 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ahn, CW; Cha, BS; Cho, MH; Kim, KR; Lee, HC; Nam, JS; Park, JS; Yoo, JS | 1 |
| Bastien, C; Chappard, D; Jouzeau, JY; Koufany, M; Moulin, D; Netter, P; Weryha, G | 1 |
| Afarideh, M; Azizi, R; Ebadi, M; Esteghamati, A; Mousavizadeh, M; Nakhjavani, M; Noshad, S | 1 |
| Avtanski, D; Babushkin, N; Hirth, Y; Poretsky, L; Seto-Young, D; Sharma, D; Sy, V | 1 |
| Chen, A; Chen, P; Dong, Y; Guo, F; Huang, S; Huang, X; Xu, F | 1 |
2 trial(s) available for pioglitazone and osteoprotegerin
| Article | Year |
|---|---|
Effect of pioglitazone on serum concentrations of osteoprotegerin in patients with type 2 diabetes mellitus.
Topics: Adiponectin; Adult; Aged; Biomarkers; Blood Glucose; C-Reactive Protein; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Male; Metformin; Middle Aged; Osteoprotegerin; Pioglitazone; Thiazolidinediones | 2011 |
The comparative effect of pioglitazone and metformin on serum osteoprotegerin, adiponectin and intercellular adhesion molecule concentrations in patients with newly diagnosed type 2 diabetes: a randomized clinical trial.
Topics: Adiponectin; Anti-Inflammatory Agents, Non-Steroidal; Blood Glucose; C-Reactive Protein; Diabetes Mellitus, Type 2; Female; Follow-Up Studies; Glycated Hemoglobin; Humans; Hyperglycemia; Hypoglycemic Agents; Inflammation Mediators; Intercellular Adhesion Molecule-1; Male; Metformin; Middle Aged; Osteoprotegerin; Pioglitazone; Sex Characteristics; Thiazolidinediones | 2015 |
3 other study(ies) available for pioglitazone and osteoprotegerin
| Article | Year |
|---|---|
The peroxisome proliferator-activated receptor γ agonist pioglitazone preserves bone microarchitecture in experimental arthritis by reducing the interleukin-17-dependent osteoclastogenic pathway.
Topics: Animals; Arthritis, Experimental; Bone and Bones; Bone Density; Interleukin-17; Male; Osteoclasts; Osteoprotegerin; Pioglitazone; PPAR gamma; Radiography; RANK Ligand; Rats; Rats, Inbred Lew; Severity of Illness Index; Signal Transduction; Synovial Membrane; Thiazolidinediones | 2013 |
In Vitro Effects of Pioglitazone on the Expression of Components of Wnt Signaling Pathway and Markers of Bone Mineralization.
Topics: beta Catenin; Biomarkers; Calcification, Physiologic; Calcium; Cell Survival; Fetus; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Gene Expression Regulation; Humans; Integrin-Binding Sialoprotein; Minerals; Osteoblasts; Osteoprotegerin; Phosphates; Pioglitazone; PPAR gamma; RNA, Messenger; Thiazolidinediones; Wnt Signaling Pathway | 2016 |
Pioglitazone affects the OPG/RANKL/RANK system and increase osteoclastogenesis.
Topics: Animals; Bone Resorption; Cell Communication; Cell Differentiation; Cell Line; Cells, Cultured; Hypoglycemic Agents; Mice; Monocytes; Osteoblasts; Osteoclasts; Osteoprotegerin; Pioglitazone; RANK Ligand; Receptor Activator of Nuclear Factor-kappa B; Thiazolidinediones | 2016 |